Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of JNJ-73763989 in Healthy Japanese Adults
NCT04002752Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tomligisiran in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Time to Reach Maximum Observed Plasma Concentration at 48 hours and 3 more. Started Jul 2019; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04002752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002752.